Recombivax-HB: perspectives past, present and future (Q35728555)

9 August 2017

1 reference

title

Recombivax-HB: perspectives past, present and future (English)

1 reference

9 August 2017

0 references

1

Charmaine Venters

1 reference

9 August 2017

3

William Cassidy

1 reference

9 August 2017

William Graham

2

1 reference

PubMed ID

15056038

9 August 2017

language of work or name

1 reference

1 April 2004

1 reference

Expert Review of Vaccines

9 August 2017

1 reference

9 August 2017

3

1 reference

9 August 2017

2

1 reference

9 August 2017

119-129

1 reference

The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture

9 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Immunogenicity of recombinant yeast hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

A hepatitis B vaccination program targeting adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Adolescent hepatitis B immunization: making it simpler

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Hepatitis B virus infection among children born in the United States to Southeast Asian refugees

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Immunological memory and protective immunity: understanding their relation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Do we need 3 doses of hepatitis B vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Hepatitis B vaccination and the risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

School-based hepatitis B vaccination programme and adolescent multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.119

21 January 2018

Identifiers

DOI

10.1586/14760584.3.2.119

1 reference

9 August 2017

1 reference

PubMed ID

15056038